Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced its annual results for 2024, highlighting a 25.5% increase in revenue and a significant reduction in losses compared to the previous year. The company made notable advancements in its ADC and novel drug candidate assets, including the marketing authorization of sac-TMT for specific cancer treatments in China, marking a significant milestone in its product commercialization efforts.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of advanced drug conjugates (ADCs) and novel drug candidates. The company is engaged in the research and development of innovative therapies, particularly targeting oncology and other critical diseases.
YTD Price Performance: 59.22%
Average Trading Volume: 372,172
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.94B
See more data about 6990 stock on TipRanks’ Stock Analysis page.